Stayble Therapeutics AB

STU:4K4 (Sweden)   Ordinary Shares
€ 0.02 (+9.46%) Apr 26
At Loss
P/B:
0.32
Market Cap:
€ 634.00K ($ 679.00K)
Enterprise V:
€ -1.19M ($ -1.27M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:

Business Description

Description
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.78
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -30.7
3-Year EPS without NRI Growth Rate -27.5

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 69.57
9-Day RSI 56.98
14-Day RSI 52.4
6-1 Month Momentum % -96.02
12-1 Month Momentum % -87.42

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.28
Quick Ratio 4.28
Cash Ratio 3.88

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -16.9
Shareholder Yield % -429.54

Profitability Rank

Name Current Vs Industry Vs History
ROE % -111.23
ROA % -90.07
ROIC % -283.75
ROCE % -107.02

Financials (Next Earnings Date:2024-05-23 Est.)

STU:4K4's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Stayble Therapeutics AB Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.094
Beta 0
Volatility % 168.13
14-Day RSI 52.4
14-Day ATR (€) 0.005181
20-Day SMA (€) 0.01484
12-1 Month Momentum % -87.42
52-Week Range (€) 0.008 - 0.524
Shares Outstanding (Mil) 31.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Stayble Therapeutics AB Filings

Filing Date Document Date Form
No Filing Data

Stayble Therapeutics AB Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Stayble Therapeutics AB Frequently Asked Questions

What is Stayble Therapeutics AB(STU:4K4)'s stock price today?
The current price of STU:4K4 is €0.02. The 52 week high of STU:4K4 is €0.52 and 52 week low is €0.01.
When is next earnings date of Stayble Therapeutics AB(STU:4K4)?
The next earnings date of Stayble Therapeutics AB(STU:4K4) is 2024-05-23 Est..
Does Stayble Therapeutics AB(STU:4K4) pay dividends? If so, how much?
Stayble Therapeutics AB(STU:4K4) does not pay dividend.

Press Release

Subject Date
No Press Release